Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

Summary

The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment. Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous injection) as add-on to metformin for 32 weeks. Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar.

Timeline

Start

2024-04

Primary completion

2025-08-30

Completion

2025-12-30

Drugs

Indications